ONO-5046Na
Phase 2Small molecule
Ono Pharmaceutical Co. LtdONO-5046Na is one of 17 small molecule programs targeting Acute Respiratory Failure. It is currently in Phase 2.
1
Indications
1
Total Trials
0
Active Trials
16
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
28 competitors in Acute Respiratory Failure
#DrugCompanyPhaseTrials
1Heparin Sodium
BBaxter Healthcare Corporation
Phase 3
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Zithromax
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Neupogen
EEastern Cooperative Oncology Group
Phase 3
Activase
RochePhase 2
Medrol
PfizerPhase 2
Aurlumyn
BBTG International Inc.
Phase 2
ABX464
AAbivax S.A.
Phase 3
Mesenchymal Stromal Cells
Mario Negri Institute for Pharmacological ResearchPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ONO-5046Na. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company